A PYMNTS Company

US: Court ruling prohibits Actavis from withdrawing cheaper Alzheimer’s drug

By  |  May 24, 2015

A federal appeals court has rejected a drug manufacturer’s appeal and affirmed a judge’s order that Actavis PLC keep distributing its widely used Alzheimer’s medication until after its patent expires this summer.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    New York Attorney General Eric Schneiderman had sought the order and called the Court of Appeals ruling a victory for consumers. His office says the drug Namenda should remain on shelves 30 days after the patent expires July 11.

    He alleged anti-trust and state law violations by Actavis in an effort to push patients to its new patented drug and avoid losses from cheaper generics.

    Dublin-based Actavis says its new drug Namenda XR is better and demand is growing. It’s taken once daily, not twice daily.

     

    Full content: The Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.